Hepatitis C Clinical Trial
Official title:
The Use of MRI Apparent Diffusion Coefficient Value (ADC Value) to Assess Liver Cirrhosis in Hepatitis C Patients: Observational Case Control Study
Hepatitis is known to induce severe liver diseases. The evaluation of the severity of liver cirrhosis is very important for the selection of appropriate treatment plan and the monitoring of patient response to treatment, accurate staging of liver fibrosis is critical because it determines the indication of antiviral treatment and prognosis of patients with chronic viral hepatitis, DWI is a particularly appealing method for the diagnosis of liver fibrosis because it is easy to implement and process, without the need for contrast agents. Apparent diffusion coefficient (ADC) has been shown to be a promising marker of fibrosis and cirrhosis.
Introduction Hepatitis is known to induce severe liver diseases such as liver cirrhosis and
liver cancer which are serious threats to public health. The evaluation of the severity of
liver cirrhosis is very important for the selection of appropriate treatment plan and the
monitoring of patient response to treatment [1].
Noninvasive Child-Pugh classification is a common method to assess liver function, treatment
outcome and prognosis in patients with chronic liver cirrhosis [2].
Accurate staging of liver fibrosis (commonly determined by liver biopsy) is critical because
it determines the indication of antiviral treatment and prognosis of patients with chronic
viral hepatitis. For example, patients with cirrhosis are at higher risk of end-stage liver
disease, portal hypertension, and hepatocellular carcinoma and are less likely to respond to
antiviral therapy [8-9].
However, liver biopsy is relatively invasive, limited by sample size, and difficult to
repeat. Thus, noninvasive tools to assess the degree of fibrosis of the whole liver are
urgently needed. Several noninvasive MRI techniques have been investigated for the diagnosis
of liver fibrosis and cirrhosis, including diffusion weighted imaging (DWI) [20-24], MR
Elastography [25], and perfusion-weighted imaging [26-27].
DWI is a particularly appealing method for the diagnosis of liver fibrosis because it is easy
to implement and process, without the need for contrast agents. Apparent diffusion
coefficient (ADC) has been shown to be a promising marker of fibrosis and cirrhosis by
several independent investigators [20-24].
Recently magnetic resonance Diffusion Weighted Imaging (DWI) has become another noninvasive
approach to assess liver cirrhosis by analyzing the changes of water diffusion based on the
apparent diffusion coefficient (ADC) [3].
Several studies showed that ADC values of cirrhotic liver were correlated with the results of
Child-Pugh classification for the evaluation of the severity of liver cirrhosis [4-7].
However, whether ADC values of cirrhotic liver are correlated with the results of Child-Pugh
classification, it remains unclear. The DWI is a specific MRI technique that evaluates the
motion of, mainly, water protons in the tissue. The apparent diffusion coefficient (ADC) is
the most frequently used DWI measure and provides useful information about inflammation,
perfusion and local cell breakdown. The ADC map is calculated based on exponential fitting of
DWI over multiple b-values and is used to measure diffusion quantitatively. Prior studies
have shown that in liver fibrosis water diffusion may be diminished by extracellular collagen
fibers and proteoglycans, thus, reduced ADC values have been reported for liver fibrosis.
[10,11,12,13,14,15,16,17,18,20].
These findings suggest DWI could be a useful imaging technique to evaluate fibrosis. In more
recent studies, researchers examined the relationship between the stages of hepatic fibrosis
and ADC values [14,15,16,19,20].
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 |